Park Ella S Y, Rabinowits Guilherme, Hamnvik Ole-Petter R, Dagi Linda R
Yonsei University College of Medicine, Seoul, South Korea.
Medical Oncology Department, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
J AAPOS. 2018 Aug;22(4):310-312. doi: 10.1016/j.jaapos.2018.01.006. Epub 2018 Apr 4.
We present the first reported case of Graves' orbitopathy induced by pembrolizumab, a new FDA-approved drug used for the treatment of multiple refractory solid tumors and classic Hodgkin lymphoma. Pembrolizumab elicits T-lymphocyte proliferation; we suspect that thyroid eye disease may result in some cases.
我们报告了首例由帕博利珠单抗引起的格雷夫斯眼眶病病例，帕博利珠单抗是一种新的经美国食品药品监督管理局批准用于治疗多种难治性实体瘤和经典霍奇金淋巴瘤的药物。帕博利珠单抗可引起T淋巴细胞增殖；我们怀疑在某些情况下可能会导致甲状腺眼病。
